All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @madisonmulkey on TikTok · 186s|Watch on TikTok

@madisonmulkey's semaglutide success story, fact-checked

Madison Mulkey

TikTok creator

2.5M viewsWatch on TikTok

Quick answer

Semaglutide is a GLP-1 receptor agonist that mimics hormones that regulate blood sugar and appetite. In the landmark STEP 1 trial, 2.4mg weekly semaglutide led to 14.9% average weight loss over 68 weeks. The medication requires ongoing use to maintain weight loss benefits.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @madisonmulkey's semaglutide success story, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@madisonmulkey's semaglutide success story, fact-checked" from Madison Mulkey. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a GLP-1 receptor agonist that mimics hormones that regulate blood sugar and appetite.

The reason this review is not generic is the source wording and the canonical claim label "glp1 as always im not a doctor just an overweight girl with f." In this clip, the useful excerpt is: "As always, im not a doctor 😊 just an overweight girl with food addiction who found something that finally made a difference!" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

74.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide is a GLP-1 receptor agonist that mimics hormones that regulate blood sugar and appetite.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide is a GLP-1 receptor agonist that mimics hormones that regulate blood sugar and appetite. In the landmark STEP 1 trial, 2.4mg weekly semaglutide led to 14.9% average weight loss over 68 weeks. The medication requires ongoing use to maintain weight loss benefits.
  • Semaglutide led to 14.9% average weight loss over 68 weeks in the STEP 1 trial, making Madison's success typical
  • 74.2% of trial participants experienced side effects, mostly gastrointestinal issues like nausea

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide led to 14.9% average weight loss over 68 weeks in the STEP 1 trial, making Madison's success typical
  • 74.2% of trial participants experienced side effects, mostly gastrointestinal issues like nausea
  • The medication costs $1,200-$1,500 monthly and many insurance plans don't cover weight loss use
  • Participants regained two-thirds of lost weight within a year of stopping treatment in follow-up studies
  • 86.4% of people in clinical trials lost at least 5% of their body weight, but 13.6% saw minimal results
  • Madison's disclaimers and personal framing make this more responsible than typical health TikToks
  • Personal success stories can't predict individual results or replace medical consultation

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok actually claim?

Madison Mulkey shares her personal experience using semaglutide (the active ingredient in Ozempic and Wegovy) for weight loss. She describes herself as someone with food addiction who finally found something that "made a difference."

The video is responsible in its disclaimers. She explicitly states she's not a doctor and is sharing personal experience rather than medical advice. This kind of transparency is refreshing on a platform where health misinformation spreads quickly.

The hashtags suggest she's using semaglutide through a weight management program, possibly combining it with other approaches like Weight Watchers. This multimodal approach matches how these medications are typically prescribed.

Does her experience match clinical data?

Madison's positive response to semaglutide is consistent with large-scale clinical trials. The STEP 1 trial (Wilding et al., NEJM, 2021) found that 68 weeks of 2.4mg semaglutide led to 14.9% average body weight loss compared to 2.4% with placebo.

What's particularly relevant is her mention of food addiction. Semaglutide works by activating GLP-1 receptors in the brain that regulate appetite and food intake. The STEP 1 trial showed 86.4% of participants lost at least 5% of their body weight, suggesting most people do see meaningful results.

Her experience isn't unique or surprising based on the data. The medication has shown consistent efficacy across multiple large trials, though individual responses vary significantly.

What doesn't she mention that matters?

Madison's brief video skips several important realities about semaglutide treatment. She doesn't discuss side effects, which affected 74.2% of participants in STEP 1 trials, mostly gastrointestinal issues like nausea and diarrhea.

There's no mention of the medication's cost, which runs roughly $1,200-$1,500 monthly without insurance coverage. Many insurance plans don't cover semaglutide for weight loss, making it inaccessible for many patients.

She also doesn't address what happens when you stop taking it. The STEP 1 withdrawal extension study showed participants regained about two-thirds of their lost weight within a year of stopping treatment. This isn't a short-term fix.

Should you trust this kind of content?

Madison's approach is more trustworthy than most health TikToks because she includes clear disclaimers and doesn't make medical claims. She's sharing personal experience, not giving advice.

However, success stories can create unrealistic expectations. While semaglutide is effective for most people, the STEP trials also showed that 13.6% of participants didn't achieve even 5% weight loss. Individual results really do vary.

The real issue isn't with Madison's content but with how viewers might interpret it. Personal testimonials, no matter how honest, can't replace conversations with healthcare providers about whether this medication is appropriate for your specific situation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Madison Mulkey · TikTok creator

2.5M views on this video

As always, im not a doctor 😊 just an overweight girl with food addiction who found something that finally made a difference! #semaglutide #weightwatchers #healthjourney #weightloss #fitness #fitness

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide led to 14.9% average weight loss over 68 weeks?

Semaglutide led to 14.9% average weight loss over 68 weeks in the STEP 1 trial, making Madison's success typical

What does the video say about 74.2% of trial participants experienced side effects, mostly gastrointestinal?

74.2% of trial participants experienced side effects, mostly gastrointestinal issues like nausea

What does the video say about the medication costs $1,200-$1,500 monthly?

The medication costs $1,200-$1,500 monthly and many insurance plans don't cover weight loss use

What does the video say about participants regained two-thirds of lost weight within a year of?

Participants regained two-thirds of lost weight within a year of stopping treatment in follow-up studies

What does the video say about 86.4% of people in clinical trials lost at least 5%?

86.4% of people in clinical trials lost at least 5% of their body weight, but 13.6% saw minimal results

What does the video say about madison's disclaimers?

Madison's disclaimers and personal framing make this more responsible than typical health TikToks

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Madison Mulkey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.